Walgreens has sold more shares of drug distributor Cencora for proceeds of about $300 million in the latest effort to pay ...

The sale netted about $300 million for Walgreens and shrinks the company’s stake in Cencora to approximately 6%, down from 10 ...

In yet another move to pay down debt that matures in 2026, Walgreens Boots Alliance announced last night it would receive ...

Walgreens and Cencora have been working together since 2013, when the drug distributor was still known as AmerisourceBergen. But recently Walgreens has been winnowing its stake in Cencora as the ...

Cencora is now targeting an 8% to 10% rise in revenue for the full fiscal year, a lift from its previous guidance for 7% to 9% growth. Sales are expected to rise 9% to 11% in its U.S. healthcare ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

Drug distributor Cencora raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines.

After back-to-back years of 20%-plus gains in 2023 and 2024, the S&P 500 is off to another strong start to 2025. However, the S&P 500's forward earnings multiple of 22 (as of Feb. 7) was also ...